Curated Evidence Map
The studies below represent key biological signals underlying the SweetFreedom Sequential Restoration model.
They are not presented as proof of therapeutic efficacy. They are presented as converging evidence that justifies structured clinical investigation – especially beyond the honeymoon window.
How to Use This Page
- Core Scientific Foundation: the minimum set of pillars that support the model.
- Extended Library: additional depth for clinicians, researchers, and reviewers.
Layer 1 – Core Scientific Foundation
1) Beta Cell Stress and Immune Recruitment
Roep BO, et al. – Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).
Nature Reviews Endocrinology, 2021.
Signal: positions beta-cell stress (ER/oxidative/inflammatory) as an upstream driver that can amplify immune targeting – reframing T1D as a β-cell-involved disease process.
2) Gut-Microbiome Changes Precede Autoimmunity (TEDDY)
Vatanen T, et al. – The human gut microbiome in early-onset type 1 diabetes from the TEDDY study.
Nature, 2018.
Signal: longitudinal metagenomics shows microbiome functional shifts can precede islet autoimmunity – supporting the gut as an early, measurable leverage point.
3) Enteroviral Persistence and Islet Stress (nPOD-Virus)
Richardson SJ, et al. – Joint analysis of the nPOD-Virus Group data.
Diabetologia, 2025.
Signal: the largest coordinated tissue analysis to date supports an association between enterovirus markers and T1D pancreas tissue – consistent with persistent, low-grade islet stress rather than an isolated acute trigger.
4) The Islet as an Ecosystem – Alpha Cell Dysfunction
Doliba NM, et al. – Alpha cell dysfunction in type 1 diabetes.
Journal of Clinical Investigation, 2022.
Signal: identifies α-cell dysfunction early in the autoimmune trajectory, arguing that restoration targets the islet ecosystem (α-β signaling), not β-cells alone.
5) Human Beta Cell Regeneration Signal (Harmine + GLP-1)
Rosselot C, et al. – Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo.
Science Translational Medicine, 2024.
Signal: demonstrates multi-fold expansion of transplanted human β-cell mass in vivo under defined signals – strengthening biological plausibility of regeneration if the environment becomes permissive.
Layer 2 – Extended Library
A) Gut-Microbiome and SCFA Mechanisms
Mariño E, et al. – Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes.
Nature Immunology, 2017.
Signal: SCFA-linked microbial metabolites can reduce diabetogenic immune responses and protect against T1D in preclinical models – mechanistic support for metabolite-driven immune modulation.
Bell KJ, et al. – Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation.
Microbiome, 2022.
Signal: human supplementation study associated with shifts in microbiota and immune parameters – a clinical signal that metabolite-focused approaches can move measurable biology.
de Groot PF, et al. – Oral butyrate does not affect innate immunity and islet autoimmunity in longstanding type 1 diabetes: a randomized controlled trial.
Diabetologia, 2020.
Signal: an important negative study – simple butyrate alone did not shift immune endpoints in longstanding T1D, supporting the case for sequencing and multi-factor restoration rather than single-agent stacking.
Tougaard NH, et al. – Effects of butyrate supplementation on inflammation and kidney parameters in type 1 diabetes: a randomized, double-blind, placebo-controlled trial.
Journal of Clinical Medicine, 2022.
Signal: another controlled human study suggesting limited impact of butyrate alone in a specific T1D cohort – reinforcing that context and sequence likely matter.
de Groot P, et al. – Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomized controlled trial.
Gut, 2021.
Signal: human intervention signal showing microbiome-targeted intervention associated with preservation of residual β-cell function in new-onset T1D.
Ismail HM, et al. – Evaluating the effect of prebiotics on the gut microbiome profile and β cell function in youth with newly diagnosed type 1 diabetes: protocol of a pilot randomized controlled trial.
Pilot and Feasibility Studies, 2023.
Signal: outlines a biomarker-rich clinical framework to test whether targeted prebiotics can shift SCFAs, microbiome composition, glycemia, and β-cell function in youth.
B) Viral Triggers, Persistence, and Tissue Evidence
Rodriguez-Calvo T, et al. – Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes.
Diabetologia, 2025.
Signal: extensive organ-donor analysis linking VP1 positivity with HLA-I hyperexpression, including in preclinical stages – supporting a model of viral-associated, stress-amplified immune visibility.
Krogvold L, et al. – Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes (DiViD study).
Diabetes, 2015.
Signal: rare access to living-patient pancreatic tissue shortly after diagnosis, supporting the plausibility of low-grade enteroviral presence at/near onset.
C) Environmental Exposome and Beta Cell Vulnerability
Tang Y, et al. – Environmental mechanisms influencing the pathogenesis and progression of type 1 diabetes.
International Journal of Molecular Sciences, 2025.
Signal: integrates evidence that diverse exposures can converge on shared pathways (oxidative stress, mitochondrial dysfunction, ER stress, immune dysregulation) – supporting multi-factor stress reduction as a rational frame.
D) Regeneration and Plasticity – Foundational Papers
Wang P, et al. – A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
Nature Medicine, 2015.
Signal: establishes DYRK1A inhibition as a key lever for inducing human β-cell proliferation – a foundational regeneration mechanism.
Ackeifi C, et al. – GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
Science Translational Medicine, 2020.
Signal: demonstrates synergy that improves proliferation and functional outputs in human islets, strengthening the case that regeneration signals can be engineered, not assumed absent.
E) Cross-Discipline Integration
SweetFreedom Position Papers (framework documents):
- A Multi-Factorial Approach to Type 1 Diabetes
- A New Understanding of Type 1 Diabetes
These are not presented as clinical guidance. They map how the pillars above connect into a testable sequence.
Notes and Boundaries
- This page is for research transparency and education.
- It does not provide medical advice.
- Listing a study here does not imply proof of clinical efficacy.
If you are a clinician or researcher interested in reviewing the full dossier (including pilot architecture and measurement plan), please contact us.
[ Request a Clinical Discussion ]
